Arvinas, Inc. (ARVN): Long-Term Debt
$600.0K
As of 2025-12-31
$500.0K
As of 2026-06-30
-15.7%
3-year compound annual growth
-21.4%
5-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $600.0K | -25.0% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $800.0K | -20.0% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $1.00M | 0.0% | 2025-02-11, Balance as of period end |
| 2022-12-31 | $1.00M | 0.0% | 2023-02-23, Balance as of period end |
| 2021-12-31 | $1.00M | -50.0% | 2022-02-28, Balance as of period end |
| 2020-12-31 | $2.00M | 0.0% | 2021-03-01, Balance as of period end |
| 2019-12-31 | $2.00M | -7.8% | 2020-03-16, Balance as of period end |
| 2018-12-31 | $2.17M | n/a | 2019-03-26, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Arvinas, Inc. (ARVN) | 2025-12-31 | $600.0K | -25.0% |
| Harrow, Inc. (HROW) | 2025-12-31 | $250.00M | -4.8% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $99.00M | +106.3% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $220.34M | -5.1% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $48.25M | +24.7% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $146.10M | +20.2% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $22.68M | -66.7% |
| MannKind Corp (MNKD) | 2025-12-31 | $354.64M | +883.7% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $291.77M | -1.4% |
Compare ARVN, HROW, RCUS, XERS side by side · Screen every company in Pharmaceutical Preparations ↗